<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446497</url>
  </required_header>
  <id_info>
    <org_study_id>H-1008-059-327</org_study_id>
    <secondary_id>KHP01</secondary_id>
    <nct_id>NCT01446497</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma</brief_title>
  <official_title>Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic&#xD;
      (Timolol) ophthalmic solutions in normal tension glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of&#xD;
           glaucoma type)&#xD;
&#xD;
        -  Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by&#xD;
           suppression of aqueous humor production and increasement of uveoscleral outflow&#xD;
&#xD;
        -  Timolol (non selective beta blocker): suppression effect of aqueous humor production&#xD;
&#xD;
        -  Combigan (fixed combination of brimonidine &amp; timolol): more lowering effect of&#xD;
           intraocular pressure and enhancing the compliance of glaucoma patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in intraocular pressure at 12 weeks</measure>
    <time_frame>12 weeks after the initial treatment</time_frame>
    <description>Intraocular pressure (IOP) check by Goldmann applanation tonometry with topical anesthetic eyedrop</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non selective beta blocker, aqueous humor suppressant ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combigan (Timolol/Brimonidine) combination drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine: alpha-2 agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine/Timolol mixed combination</intervention_name>
    <description>Twice per day, 1 drop at each time</description>
    <arm_group_label>Timolol</arm_group_label>
    <other_name>Combigan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Twice per day, 1 drop at each time</description>
    <arm_group_label>Combigan (Timolol/Brimonidine) combination drug</arm_group_label>
    <other_name>Timoptic XE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 18 years old&#xD;
&#xD;
          -  baseline IOP under 22 mmHg,both anterior chamber angle &gt; Grade 3~4 by Shaffer grading&#xD;
             system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IOP over 22 mmHg by Goldmann applanation tonometer&#xD;
&#xD;
          -  other types of glaucoma except open angle&#xD;
&#xD;
          -  other IOP lowering treatment&#xD;
&#xD;
          -  chronic or recurrent Hx. of ocular inflammation&#xD;
&#xD;
          -  using contact lens&#xD;
&#xD;
          -  any other ocular disease that could affect visual field examination (diabetic&#xD;
             retinopathy, macular disease, uveitis, scleritis, optic neuritis, anterior ischemic&#xD;
             optic neuropathy)&#xD;
&#xD;
          -  intraocular or glaucoma surgery within 6 months&#xD;
&#xD;
          -  Hx. of allergic reaction to timolol or brimonidine&#xD;
&#xD;
          -  bronchial asthma&#xD;
&#xD;
          -  moderate to severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  2~3 degree A-V block,&#xD;
&#xD;
          -  MAO inhibitor use&#xD;
&#xD;
          -  anti depressant use&#xD;
&#xD;
          -  untreated pheochromocytoma&#xD;
&#xD;
          -  pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Ho Park, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki Ho Park, M.D., Ph.D.</last_name>
    <phone>+82-2-2072-2438</phone>
    <phone_ext>3172</phone_ext>
    <email>kihopark@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Hoon Jeong, M.D.</last_name>
    <phone>+82-2-2072-2438</phone>
    <phone_ext>3110</phone_ext>
    <email>j2h23@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Ho Park, M.D., Ph.D.</last_name>
      <phone>+82-2-2072-2438</phone>
      <phone_ext>3172</phone_ext>
      <email>kihopark@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jae Hoon Jeong, M.D.</last_name>
      <phone>+82-2-2072-2438</phone>
      <phone_ext>3110</phone_ext>
      <email>j2h23@hanmali.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>September 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>October 3, 2011</last_update_submitted>
  <last_update_submitted_qc>October 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal tension glaucoma</keyword>
  <keyword>Antiglaucoma ophthalmic solution</keyword>
  <keyword>Brimonidine</keyword>
  <keyword>Timolol</keyword>
  <keyword>Combination drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

